8 nominees · 3 ballot items.
Election of eight directors; Advisory (non-binding) vote to approve named executive officer compensation (Say-on-Pay); Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Elect eight nominees (Rohit Ghai, Peter Gyenes, Richard Jones, Christopher Lafond, Dianne Ledingham, Sharon Rowlands, Alan Trefler, and Larry Weber) to the Board of Directors for one-year terms.
A non-binding advisory vote to approve the compensation of the company's named executive officers as disclosed in the proxy statement.
This non-binding management proposal asks shareholders to approve the company’s 2025 executive compensation as disclosed in the proxy. Management seeks endorsement to confirm alignment of pay with performance; the Compensation Committee uses the vote as feedback when designing future pay programs. The CD&A details pay elements including base salary, CICP bonuses tied to ACV growth and Rule of 40, time-based and performance-based equity awards, severance and change-in-control protections, and other benefits. The company notes strong 2025 financial performance, overachievement of targets, and prior high shareholder support (98% in 2025), framing a rationale for continued support. Approval is advisory and not binding, but the board recommends a FOR vote and will consider results when setting compensation. The vote is presented in the context of robust disclosure about performance metrics (ACV growth, Rule of 40) and pay-for-performance alignment, including detailed pay versus performance tables and potential payments upon termination. Investors evaluating the proposal should weigh the company’s performance-based structures and historical shareholder support against any governance concerns about CEO duality or pay quantum; the board emphasizes compensation committee oversight and alignment with long-term shareholder interests.
Ratify the Audit Committee's selection of Deloitte & Touche LLP as the company’s independent registered public accounting firm for fiscal year ending December 31, 2026.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | VANGUARD PORTFOLIO MANAGEMENT LLC | 3.8% | 6,361,923 | $271M |
| 2 | BlackRock, Inc. | 3.5% | 5,904,374 | $251M |
| 3 | AQR CAPITAL MANAGEMENT LLC | 2.7% | 4,497,814 | $189M |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 2.5% | 4,160,456 | $177M |
| 5 | STATE STREET CORP | 1.7% | 2,856,028 | $122M |
| 6 | BlackRock, Inc. | 1.6% | 2,658,710 | $113M |
| 7 | DIMENSIONAL FUND ADVISORS LP | 1.4% | 2,317,837 | $99M |
| 8 | WELLINGTON MANAGEMENT GROUP LLP | 1.4% | 2,317,704 | $99M |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 1.3% | 2,174,435 | $93M |
| 10 | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 1.3% | 2,139,638 | $91M |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.